Morphine or Ketamine for Analgesia
Launched by COLUMBIA UNIVERSITY · Feb 17, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a medication called sub-dissociative ketamine is just as effective as morphine for relieving severe pain in children who have abdominal pain or isolated fractures in their arms or legs. Morphine is commonly used for this purpose, but it can have serious side effects and raise concerns for both doctors and parents. The researchers hope that ketamine might be a safer option that could help avoid complications and improve overall well-being in the long run.
To be eligible for this trial, children must be between the ages of 2 and 17, have a pain score of 6 out of 10 or higher, and need intravenous (IV) morphine for pain relief as determined by their doctor. However, children who have certain health issues, allergies to the medications, or other specific conditions will not be able to participate. If your child is eligible, they will receive either ketamine or morphine in a controlled setting, and their pain relief will be closely monitored. This study aims to find a better way to manage pain in young patients while keeping their safety and health in mind.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Abdominal pain or isolated long-bone extremity fracture (suspected or proven)
- • 2. Self-reported pain score of ≥ 6/10
- • 3. Requires IV morphine for analgesia as determined by the treating physician
- Exclusion Criteria:
- • 1. Weight \> 82.4 kg
- • 2. Known allergy/contraindication to morphine or ketamine
- • 3. Antecedent receipt of ketamine related to presenting complaint
- • 4. Inability to use self-report measures of pain or questionnaires
- • 5. Chronic disease associated with pain
- • 6. Chronic pain condition requiring use of opioids as outpatient
- • 7. Hemodynamic instability or critical illness per treating physician
- • 8. Altered mental state (e.g., GCS , 14 or clinical intoxication)
- • 9. Known history of schizophrenia, liver or kidney problems, or osteogenesis imperfecta
- • 10. Concern for open fracture, neurovascular compromise, or compartment syndrome
- • 11. Injuries in addition to the extremity injury (e.g., head, neck, abdomen)
- • 12. Known or reported pregnancy
- • 13. Does not speak English or Spanish
- • 14. Patient previously enrolled in this study
- • 15. Wards of state, foster children, or children in custody
About Columbia University
Columbia University, a prestigious Ivy League institution located in New York City, is a leading sponsor of clinical trials dedicated to advancing medical research and improving patient care. With a robust network of research facilities and a commitment to innovation, Columbia University collaborates with a diverse range of healthcare professionals and researchers to explore groundbreaking therapies and treatment methodologies. The university's clinical trials encompass various fields, including oncology, neurology, and public health, aiming to translate scientific discoveries into effective clinical applications. Columbia University is dedicated to maintaining the highest ethical standards and regulatory compliance, ensuring the safety and well-being of trial participants while contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Seattle, Washington, United States
Pittsburgh, Pennsylvania, United States
Sacramento, California, United States
New York, New York, United States
Milwaukee, Wisconsin, United States
Wilmington, Delaware, United States
Atlanta, Georgia, United States
Patients applied
Trial Officials
Daniel S Tsze, MD, MPH
Principal Investigator
Columbia University
Amy L Drendel, DO, MS
Principal Investigator
Medical College of Wisconsin
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported